Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HiR+X in elderly chemotherapy-intolerant DLBCL
NCT06758037Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zebtorizumab, lenalidomide, tucidinostat, PD-1 Monoclonal Antibody in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Ningbo University. Started Jan 2025; status: recruiting.
02
Drugs
zebtorizumablenalidomidetucidinostatPD-1 Monoclonal Antibody
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06758037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758037.